World Health Organisation (WHO). Accelerating access to Hepatitis C diagnostics and treatment: Overcoming barriers in low-and middle-income countries: Global Progress Report 2020. 2021.
Spearman CW, Dusheiko GM, Hellard M, Sonderup M, Hepatitis C, Lancet. (London England). 2019;394:1451–66. https://doi.org/10.1016/S0140-6736(19)32320-7.
Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of Hepatitis C virus infection and the development of hepatocellular carcinoma. Ann Intern Med. 2013;158:329. https://doi.org/10.7326/0003-4819-158-5-201303050-00005.
Van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017;66:485–93. https://doi.org/10.1016/j.jhep.2016.10.017.
Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016;64:1217–23. https://doi.org/10.1016/j.jhep.2016.01.034.
Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157:1264–e12784. https://doi.org/10.1053/j.gastro.2019.07.033.
Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153:996–e10051. https://doi.org/10.1053/j.gastro.2017.06.012.
Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long‐term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology. 2020;71:44–55. https://doi.org/10.1002/hep.30823.
Sanduzzi-Zamparelli M, Mariño Z, Lens S, Sapena V, Iserte G, Pla A, et al. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. J Hepatol. 2021;29. https://doi.org/10.1016/j.jhep.2021.11.023. S0168-8278(21)02228-5.
Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, et al. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol. 2021;3. https://doi.org/10.1016/J.JHEP.2021.11.025. S0168-8278(21)02234-0.
D’Ambrosio R, Degasperi E, Anolli MP, Fanetti I, Borghi M, Soffredini R, et al. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol. 2022;76:302–10. https://doi.org/10.1016/J.JHEP.2021.09.013.
Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516–37. https://doi.org/10.1016/j.jhep.2023.03.017.
Avila MA, Dufour J-F, Gerbes AL, Zoulim F, Bataller R, Burra P, et al. Recent advances in alcohol-related liver disease (ALD): summary of a gut round table meeting. Gut. 2020;69:764–80. https://doi.org/10.1136/gutjnl-2019-319720.
Stein E, Cruz-Lemini M, Altamirano J, Ndugga N, Couper D, Abraldes JG, et al. Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. J Hepatol. 2016;65:998–1005. https://doi.org/10.1016/j.jhep.2016.06.018.
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. https://doi.org/10.1038/nrgastro.2017.109.
Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904. https://doi.org/10.1016/j.jhep.2018.05.036.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123–33. https://doi.org/10.1002/hep.29466.
Benhammou JN, Moon AM, Pisegna JR, Su F, Vutien P, Moylan CA, et al. Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for Hepatitis C. Dig Dis Sci. 2021;66:2394–406. https://doi.org/10.1007/s10620-020-06457-2.
Kim NJ, Pearson M, Vutien P, Su F, Moon AM, Berry K, et al. Alcohol Use and Long-Term outcomes among U.S. Veterans who received Direct‐Acting antivirals for Hepatitis C treatment. Hepatol Commun. 2020;4:314–24. https://doi.org/10.1002/hep4.1464.
Bhurwal A, Ratta P, Yoshitake S, Pioppo L, Reja D, Dellatore P, et al. Inverse Association of Coffee with Liver Cancer Development: an updated systematic review and Meta-analysis. J Gastrointest Liver Dis. 2020. https://doi.org/10.15403/jgld-805.
Kawaguchi T, Kawaguchi A, Hashida R, Nakano D, Tsutsumi T, Kawaguchi M, et al. Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol. 2024;59:216–28. https://doi.org/10.1007/s00535-023-02060-0.
SAUNDERS JB, AASLAND OG, BABOR TF, DE LA FUENTE JR GRANTM. Development of the Alcohol Use disorders Identification Test (AUDIT): WHO Collaborative Project on early detection of persons with harmful alcohol Consumption-II. Addiction. 1993;88:791–804. https://doi.org/10.1111/j.1360-0443.1993.tb02093.x.
Babor TF, Higgins-Biddle JC, Saunders JB, Monteriro MG. AUDIT. The Alcohol Use disorders Identification Test. World Heal Organ; 2001.
Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken, NJ. USA: John Wiley & Sons, Inc.; 1987. https://doi.org/10.1002/9780470316696.
Molenberghs G, Kenward MG. Missing Data in Clinical studies. New York: Wiley; 2007. https://doi.org/10.1002/9780470510445.
Bowker AH. A test for Symmetry in Contingency tables. J Am Stat Assoc. 1948;43:572–4. https://doi.org/10.1080/01621459.1948.10483284.
World Health Organisation (WHO). Obesity and overweight. World Heal Organ; 2021.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and Mortality from Cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38. https://doi.org/10.1056/NEJMoa021423.
Sohn W, Lee HW, Lee S, Lim JH, Lee MW, Park CH, et al. Obesity and the risk of primary liver cancer: a systematic review and meta-analysis. Clin Mol Hepatol. 2021;27:157–74. https://doi.org/10.3350/cmh.2020.0176.
Gupta A, Das A, Majumder K, Arora N, Mayo HG, Singh PP, et al. Obesity is independently Associated with increased risk of Hepatocellular Cancer–related mortality. Am J Clin Oncol. 2018;41:874–81. https://doi.org/10.1097/COC.0000000000000388.
Staufer K, Huber-Schönauer U, Strebinger G, Pimingstorfer P, Suesse S, Scherzer T-M, et al. Ethyl Glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J Hepatol. 2022;77:918–30. https://doi.org/10.1016/j.jhep.2022.04.040.
Dailah HG. The influence of nurse-led interventions on diseases Management in patients with diabetes Mellitus: a narrative review. Healthcare. 2024;12:352. https://doi.org/10.3390/healthcare12030352.
Gonzalez Y, Kozachik SL, Hansen BR, Sanchez M, Finnell DS. Nurse-led delivery of brief interventions for At-Risk Alcohol Use: an integrative review. J Am Psychiatr Nurses Assoc. 2020;26:27–42. https://doi.org/10.1177/1078390319872536.